{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:17:02Z","timestamp":1763018222967,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.clml.2020.07.015","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T03:34:36Z","timestamp":1595993676000},"page":"e961-e985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7104-1163","authenticated-orcid":false,"given":"Rupa","family":"Narayan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Galligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann A.","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0442-6706","authenticated-orcid":false,"given":"Sarah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisela","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shagun","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.07.015_bib1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.07.015_bib2","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1002\/cncr.29533","article-title":"A\u00a0comparison of salvage infusional chemotherapy regimens for recurrent\/refractory multiple myeloma","volume":"121","author":"Griffin","year":"2015","journal-title":"Cancer"},{"issue":"suppl 1","key":"10.1016\/j.clml.2020.07.015_bib3","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1182\/blood-2019-121991","article-title":"Phase I study of escalating doses of carfilzomib with hyper-CVAD in patients with newly diagnosed acute lymphoblastic leukemia\/lymphoma","volume":"134","author":"Fisch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.07.015_bib4","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.clml.2017.10.008","article-title":"Modified hyperCVAD versus bortezomib-hyperCAD in patients with relapsed\/refractory multiple myeloma","volume":"18","author":"Saraceni","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.07.015_bib5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.clml.2019.05.001","article-title":"Retrospective review of the use of high-dose cyclophosphamide, bortezomib, doxorubicin, and dexamethasone for the treatment of multiple myeloma and plasma cell leukemia","volume":"19","author":"Tabchi","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.07.015_bib6","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.07.015_bib7","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood-2015-05-647636","article-title":"Guidelines for determination of the number of prior lines of therapy in multiple myeloma","volume":"126","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.07.015_bib8","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.07.015_bib9","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.07.015_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1096-8652(199606)52:2<77::AID-AJH2>3.0.CO;2-2","article-title":"HyperCVAD for VAD-resistant multiple myeloma","author":"Dimopoulos","year":"1996","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.07.015_bib11","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1080\/10428194.2018.1454595","article-title":"DCEP as a bridge to ongoing therapies for advanced relapsed and\/or refractory multiple myeloma","volume":"59","author":"Yuen","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.07.015_bib12","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood.V124.21.2139.2139","article-title":"Bortezomib in combination with dexamethasone, cyclophosphamide, etoposide, and cisplatin (V-DCEP) for the treatment of multiple myeloma","volume":"124","author":"Valla","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.07.015_bib13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.24954","article-title":"Efficacy of VDT PACE-like regimens in treatment of relapsed\/refractory multiple myeloma","volume":"93","author":"Lakshman","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.07.015_bib14","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1182\/blood.V124.21.3459.3459","article-title":"Analysis of VDT-PACE utilization in multiple myeloma patients treated at MSKCC for relapsed disease or cytoreduction and stem cell mobilization after initial induction therapy","volume":"124","author":"Beyer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.07.015_bib15","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood.V122.21.5377.5377","article-title":"VDTPACE as salvage therapy for heavily pretreated MM patients","volume":"122","author":"Buda","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.07.015_bib16","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjh.12325","article-title":"D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma","volume":"161","author":"Gerrie","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.07.015_bib17","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.leukres.2014.06.024","article-title":"First line and salvage therapy with total therapy 3\u2013based treatment for multiple myeloma\u2014an extended single center experience","volume":"38","author":"Muchtar","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2020.07.015_bib18","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood.V128.22.3377.3377","article-title":"Outcome of multiple myeloma patients treated with CARRD-PACE chemomobilization: a single-center experience","volume":"128","author":"Cowan","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.07.015_bib19","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1080\/14656566.2016.1236915","article-title":"Current treatments for renal failure due to multiple myeloma","volume":"17","author":"Gavriatopoulou","year":"2016","journal-title":"Expert Opin Pharmacother"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020303761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020303761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:16Z","timestamp":1761870916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020303761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S2152265020303761"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.07.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}